Objective We investigated the efficacy of edaravone in patients with cardioembolic stroke. Methods Cardioembolic stroke patients were treated with drip intravenous infusion of edaravone (ED group, n=141) 
Introduction
The efficacy of edaravone, a free radical scavenger, has been verified in acute ischemic stroke in a double-blind, randomized, placebo-controlled study (1) , and has been used in clinical practice in Japan. In a rat brain ischemiareperfusion model, edaravone has been shown to ameliorate brain edema (2, 3) and tissue injury (4) (5) (6) , and to delay neuronal death (7) and neurological deficits (3, 5) . On the basis of such pharmacological effects, it is suggested that edaravone may be more effective for treating patients with cardioembolic stroke than for those with other subtypes of ischemic stroke. Patients with cardioembolic stroke may experience successful thrombolysis and natural reperfusion, resulting in a so-called spectacular shrinking deficit (8) .
To our knowledge, randomized controlled studies of the efficacy of edaravone in treating acute ischemic stroke have not been reported except for the study conducted by the Edaravone Acute Brain Infarction Study Group (1) . In this report the outcome parameters were evaluated for the entire group of patients, but not in patients stratified according to clinical subtypes or severity. Furthermore, the endpoints in this study were only long-term activity of daily life (ADL) but not improvement in acute phase indices, which might indicate the presence of a neuroprotective effect at an early stage of reperfusion. There were two other non-randomized controlled studies previously reported (9, 10) , however the patients in these studies were heterogeneous, including internal carotid artery occlusion (9) , and atherothrombotic and lacunar strokes (10 
Results

Eligible patients
A total of 340 patients with the diagnosis of cardioembolic stroke defined by TOAST criteria were admitted to our hospital within 24 hours after the onset of symptoms during the 24-month study period. A total of 101 patients were classified as control group; 141 as ED group; and 98 as excluded group.
Clinical characteristics of subject groups
Thrombolytic agents including intravenous tissue plasminogen activator (IV-tPA) or selective intra-arterial urokinase (IA-UK) were administered in 4 patients (2 of the ED group and 2 of the control group) in the hyperacute phase. One patient in the control group who was treated with IV-tPA had no recanalization during admission. The second patient in the control group was treated with IA-UK, which resulted in partial recanalization soon after treatment. Two patients in the ED group were treated with IA-UK, and partial recanalization was seen after the treatment in one but not in another.
Stratified analysis of clinical characteristics of ED and control groups
